SSG
GPCR icon

Summit Securities Group’s Structure Therapeutics GPCR Stock Holding History

Summit Securities Group’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-246
Closed -$6.67K – 913
2024
Q4 		$6.67K Buy
+246
New +$8.73K ﹤0.01% 496

Other funds holding GPCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Summit Securities Group's GPCR Position: Q1 2025 in Review

Summit Securities Group sold out of Structure Therapeutics (GPCR) in Q1 2025, closing a stake of 246 shares — an estimated $6.67K sold.

Summit Securities Group first reported a position in GPCR in Q4 2024 and held it in 1 quarter. The position peaked at $6.67K in Q4 2024. 150 funds tracked by Wall St. Rank hold GPCR as of Q1 2025.

  • Summit Securities Group reported no remaining Structure Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Summit Securities Group sold 246 Structure Therapeutics shares in Q1 2025, an estimated $6.67K.
  • Summit Securities Group first reported a position in Structure Therapeutics in Q4 2024 and held it in 1 quarter.
  • Summit Securities Group's Structure Therapeutics position peaked at $6.67K in Q4 2024.
  • 150 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2025.

Based on Summit Securities Group's 13F filing for Q1 2025, filed 13 May 2025.